|Medical news of Remedium.ru portal is the most update information on pharmaceutical and medical equipment market|
Home / News
Nanomedicine market just taking shape in Russia - Chubais
The market of nanomedicine and nanomedicines is just taking shape in Russia, Director General of the Russian corporation of nanotechnologies (ROSNANO) Anatoly Chubais told a press briefing on Monday after the signing of an agreement with the Federal Bio-Medical Agency.
Noting that the annual growth of the world market of nanomedicines makes about ten percent, Chubais said, “We do not have such market, its volume is gigantic, the potential is enormous, and it is necessary to form the demand and supply.” The introduction of nanotechnologies in medicine will enable to get rid of expensive and traumatic urgent treatment methods in oncological diseases, he believes.
The ROSNANO chief noted that currently a project for the struggle with oncological diseases is under implementation not through surgeries, but by implanting nanoparticles, which destroy a cancer tumor by radiation. Most oncological patients in Russia (for instance, prostate gland cancer) are cured just in surgeries resulting frequently in grave consequences, while in developed countries about 90% of similar cases are treated without surgeries.
For his part, chief of the Federal Bio-Medical Agency Vladimir Uyba expressed confidence that the introduction of nanotechnologies in medicine, particularly in radiation medicine centers will bring huge revenues to the state. “Currently we are drafting a government resolution to create radiation medicine centers with the cost of a similar center making about 14 billion roubles and with the state target revenues amounting to about 250 billion roubles,” he pointed out. Though, according to Uyba, it is impossible to calculate the real revenues from saved human lives, as each life is precious. Each radiation medicine center is designed for 30,000 people annually, he pointed out.
“The Federal Bio-Medical Agency faces the priority task to develop the nanomedicine to make detailed research of the side affects, as the nanoparticles are amassed in the organism, and it is necessary to dose them thoroughly and study in the experimental way observing the major commandment of doctors not to do harm. Before the introduction of nanomedicines in practical medicine all of them will pass tests on biological models,” Uyba said.
For his part, Chubais believes that ROSNANO and the Federal Bio-Medical Agency “should develop their own methodical base to assess the safety in nanomedicine.”